Therapeutic options in the treatment of tinea capitis.
Tinea capitis is primarily a disease of pre-adolescent children. In North America and the UK, Trichophyton tonsurans is responsible for > 90% of cases. Microsporum canis is the predominant pathogen in certain parts of Europe. The standard of care for the treatment of tinea capitis is oral griseofulvin and so far, it remains the only medication approved by the US FDA for this condition. The newer oral antifungal agents, such as terbinafine, itraconazole and fluconazole, appear to be effective, safe and have the advantage of a shorter treatment duration. Although a significant number of clinical trials and reports have documented experience with terbinafine and itraconazole for the treatment of tinea capitis, it should be noted that only a few trials have been conducted utilising fluconazole. Both 2% ketoconazole and 1% selenium sulfide shampoos have been shown to reduce surface colony counts of dermatophytes in infected individuals, and these agents are often recommended for adjuvant therapy. This article reviews data currently available on various therapeutic alternatives for the treatment of tinea capitis and summarises all relevant clinical trials that have thus far investigated the use of these drugs for tinea capitis in the paediatric population.
Chan
Yuin-Chew
YC
Division of Pediatric Dermatology, Children's Hospital, San Diego, CA 92123, USA. ycchan@nsc.gov.sg
Friedlander
Sheila F
SF
D000935:Antifungal Agents / Q000627:therapeutic use*; D006801:Humans; D014006:Tinea Capitis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology
D000935:Antifungal Agents